123 related articles for article (PubMed ID: 3525815)
1. Polymerized phospholipid vesicles containing amphotericin B: evaluation of toxic and antifungal activities in vitro.
Mehta R; Hsu MJ; Juliano RL; Krause HJ; Regen SL
J Pharm Sci; 1986 Jun; 75(6):579-81. PubMed ID: 3525815
[TBL] [Abstract][Full Text] [Related]
2. Hemolytic and antifungal activity of liposome-entrapped amphotericin B prepared by the precipitation method.
Kim JC; Lee EO; Kim JY; Bae SK; Choi TB; Kim JD
Pharm Dev Technol; 1997 Aug; 2(3):275-84. PubMed ID: 9552455
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes.
Juliano RL; Grant CW; Barber KR; Kalp MA
Mol Pharmacol; 1987 Jan; 31(1):1-11. PubMed ID: 3807887
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro studies on liposomal formulations of amphotericin B and its derivative, N-methyl-N-D-fructosyl amphotericin B methyl ester (MFAME).
Cybulska B; Kupczyk K; Szlinder-Richert J; Borowski E
Acta Biochim Pol; 2002; 49(1):67-75. PubMed ID: 12136958
[TBL] [Abstract][Full Text] [Related]
5. Interactions of liposome-incorporated amphotericin B with kidney epithelial cell cultures.
Krause HJ; Juliano RL
Mol Pharmacol; 1988 Sep; 34(3):286-97. PubMed ID: 3419424
[TBL] [Abstract][Full Text] [Related]
6. Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulations.
Joly V; Bolard J; Saint-Julien L; Carbon C; Yeni P
Antimicrob Agents Chemother; 1992 Feb; 36(2):262-6. PubMed ID: 1605590
[TBL] [Abstract][Full Text] [Related]
7. Affinity of amphotericin B for phosphatidylcholine vesicles as a determinant of the in vitro cellular toxicity of liposomal preparations.
Jullien S; Brajtburg J; Bolard J
Biochim Biophys Acta; 1990 Jan; 1021(1):39-45. PubMed ID: 2403812
[TBL] [Abstract][Full Text] [Related]
8. Preparation by spray drying of amphotericin B-phospholipid composite particles and their anticellular activity.
Kim JC; Kim JD
Drug Deliv; 2001; 8(3):143-7. PubMed ID: 11570594
[TBL] [Abstract][Full Text] [Related]
9. Release of amphotericin B from delivery systems and its action against fungal and mammalian cells.
Legrand P; Chéron M; Leroy L; Bolard J
J Drug Target; 1997; 4(5):311-9. PubMed ID: 9169988
[TBL] [Abstract][Full Text] [Related]
10. Assessment of in vitro antifungal efficacy and in vivo toxicity of Amphotericin B-loaded PLGA and PLGA-PEG blend nanoparticles.
Moraes Moreira Carraro TC; Altmeyer C; Maissar Khalil N; Mara Mainardes R
J Mycol Med; 2017 Dec; 27(4):519-529. PubMed ID: 28797532
[TBL] [Abstract][Full Text] [Related]
11. Amphotericin B-copper(II) complex as a potential agent with higher antifungal activity against Candida albicans.
Chudzik B; Tracz IB; Czernel G; Fiołka MJ; Borsuk G; Gagoś M
Eur J Pharm Sci; 2013 Aug; 49(5):850-7. PubMed ID: 23791641
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo.
Tang X; Zhu H; Sun L; Hou W; Cai S; Zhang R; Liu F
Int J Nanomedicine; 2014; 9():5403-13. PubMed ID: 25473279
[TBL] [Abstract][Full Text] [Related]
13. Selective toxicity and enhanced therapeutic index of liposomal polyene antibiotics in systemic fungal infections.
Juliano RL; Lopez-Berestein G; Hopfer R; Mehta R; Mehta K; Mills K
Ann N Y Acad Sci; 1985; 446():390-402. PubMed ID: 3860162
[TBL] [Abstract][Full Text] [Related]
14. Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro.
Perez AP; Altube MJ; Schilrreff P; Apezteguia G; Celes FS; Zacchino S; de Oliveira CI; Romero EL; Morilla MJ
Colloids Surf B Biointerfaces; 2016 Mar; 139():190-8. PubMed ID: 26709977
[TBL] [Abstract][Full Text] [Related]
15. Study of the effects of liposomal amphotericin B on Candida albicans, Cryptococcus neoformans, and erythrocytes by using small unilamellar vesicles prepared from saturated phospholipids.
Jullien S; Contrepois A; Sligh JE; Domart Y; Yeni P; Brajtburg J; Medoff G; Bolard J
Antimicrob Agents Chemother; 1989 Mar; 33(3):345-9. PubMed ID: 2658784
[TBL] [Abstract][Full Text] [Related]
16. Anti-biofilm activity of a sophorolipid-amphotericin B niosomal formulation against Candida albicans.
Haque F; Sajid M; Cameotra SS; Battacharyya MS
Biofouling; 2017 Oct; 33(9):768-779. PubMed ID: 28946803
[TBL] [Abstract][Full Text] [Related]
17. Interactions of liposomal amphotericin B with extracellular and intracellular Candida albicans.
van Etten EW; Chander HR; Snijders SV; Bakker-Woudenberg IA
J Antimicrob Chemother; 1995 Dec; 36(6):961-74. PubMed ID: 8821595
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo antifungal activities of liposomal amphotericin B, and amphotericin B lipid complex.
Mitsutake K; Kohno S; Miyazaki Y; Noda T; Miyazaki H; Miyazaki T; Kaku M; Koga H; Hara K
Mycopathologia; 1994 Oct; 128(1):13-7. PubMed ID: 7708087
[TBL] [Abstract][Full Text] [Related]
19. Polysorbate Surfactants as Drug Carriers: Tween 20-Amphotericin B Conjugates as Anti-Fungal and Anti-Leishmanial Agents.
Ravichandran V; Kesavan V; Cojean S; Loiseau PM; Jayakrishnan A
Curr Drug Deliv; 2018; 15(7):1028-1037. PubMed ID: 29732967
[TBL] [Abstract][Full Text] [Related]
20. Nanoemulsion gel-based topical delivery of an antifungal drug: in vitro activity and in vivo evaluation.
Hussain A; Samad A; Singh SK; Ahsan MN; Haque MW; Faruk A; Ahmed FJ
Drug Deliv; 2016; 23(2):642-47. PubMed ID: 25013957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
